Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Crestone Inc
Profile last edited on: 1/28/21      CAGE: 5RDJ6      UEI: EDSLAP2J1BL8

Business Identifier: treatments for serious bacterial infections
Year Founded
2009
First Award
2010
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

6075 Longbow Drive Suite 130
Boulder, CO 80305
   (720) 289-8601
   info@crestonepharma.com
   www.crestonepharma.com
Location: Single
Congr. District: 02
County: Boulder

Public Profile

Crestone, Inc. is a drug discovery and development company focused on developing novel treatments for serious bacterial infections. The company currently has two advanced pre-clinical programs that address areas of significant and growing unmet medical need, both with novel mechanism of action agents.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
2
Conversion Rate
66.67%
Phase I Dollars
$788,972
Phase II Dollars
$4,974,384
Total Awarded
$5,763,356

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $143,960
Project Title: Preclinical Evaluation of CRS3123 for the Treatment of Helicobacter Pylori Infections
2016 2 NIH $1,627,487
Project Title: Optimization and Lead Selection of Novel Antimycobacterial Agents
2014 2 NIH $3,991,909
Project Title: Novel Dna Polymerase Inhibitors as Gram-Positive Antibacterial Agents
0 1 NIH $295,763
Project Title: A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease

Key People / Management

  Thale Cross Jarvis

  Clifford W Mason -- Director, Pharmacology

  Urs A Ochsner

  Xicheng Sun

Company News

There are no news available.